Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radionuclide-based pharmaceuticals for breast cancer imaging: state of the art.

EJNMMI radiopharmacy and chemistry·2026
Same author

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

ISGylation of γH2AX retains MDC1 and facilitates homologous recombination repair causing radioresistance in esophageal adenocarcinoma.

The Journal of biological chemistry·2026
Same author

Evolution of Esophageal Adenocarcinoma From Precursor Lesion Stem Cells.

Gastroenterology·2025
Same author

GRAIL1 Stabilizes Misfolded Mutant p53 through a Ubiquitin Ligase-Independent, Chaperone Regulatory Function.

Molecular cancer research : MCR·2024
Same author

ISG15/GRAIL1/CD3 axis influences survival of patients with esophageal adenocarcinoma.

JCI insight·2024
Same journal

Leveraging data-driven risk-adapted surveillance strategies after disease progression in locally advanced rectal cancer.

BMC cancer·2026
Same journal

Routine biomarkers map response probability in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2 blockade.

BMC cancer·2026
Same journal

Beyond side effects: treatment-related adverse events are associated with improved survival outcomes in HCC patients on atezolizumab-bevacizumab therapy.

BMC cancer·2026
Same journal

Clinical outcomes of percutaneous cryoablation for pulmonary metastases of soft tissue and bone sarcomas under local anesthesia: a single-institution retrospective cohort study.

BMC cancer·2026
Same journal

Catastrophic health expenditure and its determinant factors among patients with cancer attending Wolaita Sodo University Comprehensive Specialized Hospital, South Ethiopia.

BMC cancer·2026
Same journal

Single-session agreement of ChatGPT and Gemini treatment recommendations with multidisciplinary tumor board decisions in thoracic oncology.

BMC cancer·2026
See all related articles

Related Experiment Video

Updated: Mar 29, 2026

Multimodal Optical Imaging Platform for Studying Cellular Metabolism
04:47

Multimodal Optical Imaging Platform for Studying Cellular Metabolism

Published on: June 6, 2025

1.3K

Using second harmonic generation to predict patient outcome in solid tumors.

K Burke1, M Smid2, R P Dawes3

  • 1Department of Biomedical Engineering, University of Rochester, 207 Robert B. Goergen Hall, Box 270168, Rochester, NY, 14627, USA. Kathleen_Burke@URMC.Rochester.edu.

BMC Cancer
|November 26, 2015
PubMed
Summary
This summary is machine-generated.

Analyzing collagen structure using second harmonic generation (SHG) emission direction can predict metastatic potential in estrogen receptor positive (ER+) breast cancer. This matrix-focused approach aids in reducing chemotherapy over-treatment for ER+ lymph node-negative (LNN) patients.

More Related Videos

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia
12:25

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia

Published on: January 6, 2018

8.4K
Generation and Quantitative Analysis of Pulsed Low Frequency Ultrasound to Determine the Sonic Sensitivity of Untreated and Treated Neoplastic Cells
09:05

Generation and Quantitative Analysis of Pulsed Low Frequency Ultrasound to Determine the Sonic Sensitivity of Untreated and Treated Neoplastic Cells

Published on: July 22, 2015

11.7K

Related Experiment Videos

Last Updated: Mar 29, 2026

Multimodal Optical Imaging Platform for Studying Cellular Metabolism
04:47

Multimodal Optical Imaging Platform for Studying Cellular Metabolism

Published on: June 6, 2025

1.3K
Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia
12:25

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia

Published on: January 6, 2018

8.4K
Generation and Quantitative Analysis of Pulsed Low Frequency Ultrasound to Determine the Sonic Sensitivity of Untreated and Treated Neoplastic Cells
09:05

Generation and Quantitative Analysis of Pulsed Low Frequency Ultrasound to Determine the Sonic Sensitivity of Untreated and Treated Neoplastic Cells

Published on: July 22, 2015

11.7K

Area of Science:

  • Biophysics
  • Oncology
  • Medical Diagnostics

Background:

  • Over-treatment of chemotherapy in estrogen receptor positive (ER+), lymph node-negative (LNN) breast cancer is a significant clinical issue.
  • Accurate prediction of tumor metastatic potential is crucial for optimizing treatment strategies.
  • Second Harmonic Generation (SHG) analysis of primary tumor biopsies offers a novel approach to assess metastatic risk.

Purpose of the Study:

  • To evaluate the prognostic value of SHG emission direction in predicting metastatic outcomes in ER+, LNN breast cancer.
  • To explore the association of SHG F/B ratio with survival rates in various cancer types, including colorectal and lung adenocarcinoma.

Main Methods:

  • Retrospective analysis of SHG forward-to-backward (F/B) emission ratios in excised primary tumor tissues.
  • Correlation of F/B ratios with metastasis-free survival (MFS), overall survival (OS), and progression-free survival (PFS) in patient cohorts.
  • Inclusion of ER+ and ER-negative breast cancer, and stage I colorectal and lung adenocarcinoma patient data.

Main Results:

  • In ER+, LNN breast cancer, an increased F/B ratio was significantly associated with favorable MFS and OS.
  • Conversely, in ER+ recurrent breast cancer treated with tamoxifen, increased F/B predicted shorter PFS.
  • An increased F/B ratio in stage I colorectal adenocarcinoma correlated with poor OS, but not significantly in stage I lung adenocarcinoma.

Conclusions:

  • The SHG F/B ratio serves as a valuable tool for stratifying ER+, LNN breast cancer patients by tumor aggressiveness.
  • This matrix-focused method complements genomic approaches for improved metastatic prediction.
  • Combined predictive strategies may help reduce unnecessary patient over-treatment.